Clairvoyant has received regulatory approval for its Phase 2 trial investigating psilocybin for the treatment of alcohol use disorder (AUD).
Clairvoyant, which is developing psilocybin therapy for the treatment of AUD, received approval from the Finnish Medicines Agency (FIMEA).
The clinical trial, entitled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET).
Following the approval from FIMEA, Clairvoyant has launched the first of four planned trial sites in Finland.
CEO of Origin, Alex Somjen, commented: “Clairvoyant’s goal is to obtain approval for AUD-related psilocybin therapy in Europe, the UK, and Canada by 2026, and they have taken another step toward achieving that goal.
“The team at Origin is really pleased with their progress thus far.”
The clinical trial will be initiated in approximately 15 sites across Canada and Europe with the first site in Canada initiated in June of 2022. Several potential patients have already entered the screening process for the trial.
Origin therapeutic announced it has completed an investment in Clairvoyant Therapeutics in July 2022.
Speaking at the time of the investment, CEO of Clairvoyant, Damian Kettlewell, commented: “We are in the midst of a substance abuse crisis, and psychedelic therapies have the potential to provide patients with a new therapeutic intervention rather than having those patients be limited to options that often do not work or that may have unpleasant side effects.
“We are pleased to be working with the Origin Therapeutics team to drive our vision forward.”
